Lifordi Gains Major Investment to Advance ADC Autoimmune Therapy
Dateline Introduction Burlington, Massachusetts — November 18, 2025 — Lifordi Immunotherapeutics has announced a strategic investment from Sanofi Ventures,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Dateline Introduction Burlington, Massachusetts — November 18, 2025 — Lifordi Immunotherapeutics has announced a strategic investment from Sanofi Ventures,...
PARIS, Sept. 24, 2025 — Sanofi announced a $625 million capital expansion for its corporate venture fund, Sanofi Ventures,...
